ERISA Health Plan Lien vs Pharmacy Lien: Priority and Allocation Strategy

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 7 min read

When an ERISA health plan subrogation claim and a pharmacy lien both appear on the same PI settlement, attorneys must understand which takes priority and how to allocate proceeds to maximize client recovery. This guide covers the legal framework, allocation strategy, and why the two claims rarely compete.

This post is for informational purposes only and does not constitute legal advice.

An ERISA health plan subrogation lien and a pharmacy lien are fundamentally different obligations that attach to different settlement dollars, meaning they do not compete for priority in the traditional lien-stacking sense. The ERISA plan can only claim amounts it actually paid, while the pharmacy lien covers costs the plan never touched, allowing attorneys to allocate settlement proceeds methodically without the two claims overlapping.

• ERISA plan subrogation reaches only costs the plan actually paid or incurred, not costs covered by a separate pharmacy lien arrangement
• Pharmacy liens are private contractual obligations outside ERISA's scope, creating no priority conflict with plan subrogation rights
• Allocation strategy should address each obligation separately, applying different negotiation tools to each
• LienScripts pharmacy liens remove medication costs from the ERISA subrogation analysis entirely by keeping prescriptions off the plan's claims system
• According to James Wong, PharmD, founder of LienScripts, separating medication costs from health plan claims is the most effective way to reduce total subrogation exposure

Understanding the Two Claims

Before addressing priority, attorneys must understand that ERISA subrogation and pharmacy liens arise through entirely different legal mechanisms and target different pools of costs.

ERISA health plan subrogation is a contractual right created by the plan's Summary Plan Description (SPD). Under ERISA section 502(a)(3), self-funded plans can enforce an equitable lien by agreement against settlement proceeds to recover amounts the plan paid for injury-related treatment. The plan's claim is limited to costs it actually expended — medical bills, surgical costs, hospital stays, imaging, and any prescriptions processed through the plan's pharmacy benefit.

A pharmacy lien is a private contractual arrangement between the patient, their attorney, and a lien-based pharmacy provider. The pharmacy dispenses medications on credit with repayment deferred until case resolution. No health plan is involved. No insurance claim is filed. The lien is enforceable as a contract between the parties.

[!KEY] The two claims target fundamentally different cost pools. The ERISA plan's subrogation right attaches to what the plan paid. The pharmacy lien attaches to what the pharmacy dispensed on credit. When medications are dispensed under a pharmacy lien, the plan never pays for them, and the two claims do not overlap or compete.

Do ERISA Liens Have Priority Over Pharmacy Liens?

The question of "priority" implies that both claims are competing for the same limited pool of settlement dollars. In practice, ERISA subrogation and pharmacy liens do not create a true priority conflict because they attach to different obligations.

ERISA subrogation is enforced through equitable lien by agreement under Sereboff v. Mid Atlantic Medical Services, 547 U.S. 356 (2006). The plan's equitable lien attaches to specifically identifiable funds — the settlement proceeds — but only to the extent of amounts the plan paid. The plan cannot reach beyond its own expenditures.

A pharmacy lien is a contractual obligation enforceable under state contract law. It is not governed by ERISA, not subject to ERISA preemption, and not within the ERISA plan's equitable lien scope. The pharmacy lien amount represents a separate debt owed to a separate creditor for separate services.

[!TIP] When structuring settlement disbursements, treat the ERISA plan subrogation and pharmacy lien as parallel obligations, not competing ones. Each gets its own line in the settlement waterfall. The total of both obligations reduces the client's net recovery, but they do not reduce each other.

Allocation Strategy: The Settlement Waterfall

A well-structured settlement waterfall addresses each obligation methodically. Here is the recommended approach when both an ERISA plan subrogation claim and a pharmacy lien are present.

Step 1: Confirm the ERISA plan's actual expenditures. Request itemized EOBs and TPA claims data. Verify every line item. Remove any costs the plan did not pay, including medications dispensed under a pharmacy lien. Plans frequently include estimated pharmacy costs in their initial demand even when no pharmacy claims exist in their system.

Step 2: Apply the McCutchen common fund reduction. Under US Airways v. McCutchen, 569 U.S. 88 (2013), where the SPD is silent on attorney fees, the plan must contribute proportionately to the contingency fee. This typically reduces the plan's net recovery by 33 to 40 percent.

Step 3: Negotiate the ERISA plan amount. With the common fund reduction applied and unrelated charges removed, negotiate the final ERISA plan payment. Put the agreed amount in writing with a full release.

Step 4: Confirm the pharmacy lien amount. The pharmacy lien balance reflects the actual cost of medications dispensed. LienScripts provides a final lien statement for each case at settlement, making this figure deterministic.

Step 5: Negotiate the pharmacy lien if needed. Pharmacy lien providers, including LienScripts, work with attorneys on lien reductions when the settlement is insufficient to cover all obligations. This is a separate negotiation from the ERISA discussion.

Step 6: Disburse. Attorney fees and costs first, ERISA plan agreed amount, pharmacy lien agreed amount, remaining net to client.

[!KEY] The critical error to avoid is letting the ERISA plan's demand include pharmacy costs it never paid. Challenge every line item with EOB data. If medications were on lien, the plan has zero subrogation interest in those costs.

When the Plan Claims It Paid for Medications

Occasionally an ERISA plan's subrogation demand includes pharmacy line items even though the client was enrolled in a pharmacy lien from intake. This typically happens for one of three reasons.

Reason 1: The client filled some prescriptions through their insurance before the lien was established. If the client filled early prescriptions using their health plan benefits before the attorney enrolled them in a pharmacy lien, the plan has a legitimate subrogation interest in those specific fills. Subsequent fills under the lien are outside the plan's reach.

Reason 2: The TPA is using estimated costs. Some TPAs include standardized pharmacy cost estimates in subrogation demands without verifying actual claims data. Requesting itemized EOBs and pharmacy claims records will expose the estimation.

Reason 3: The client filled non-injury-related prescriptions through the plan. If the client has ongoing prescriptions unrelated to the injury (blood pressure medication, diabetes management), those may appear in the TPA's records but are not injury-related and not subject to the subrogation clause. Challenge the causal connection.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "We maintain complete dispensing records for every case. When a TPA claims pharmacy costs, attorneys can compare the TPA's records against the LienScripts dispensing log to identify exactly which medications were on lien and which, if any, went through the plan."

Montanile Leverage in Dual-Obligation Cases

When both an ERISA subrogation claim and a pharmacy lien are present, Montanile v. Board of Trustees, 577 U.S. 136 (2016) provides additional strategic leverage.

Under Montanile, an ERISA plan's equitable lien attaches only to specifically identifiable, traceable funds in the beneficiary's possession. Once settlement proceeds are dissipated into non-traceable general assets, the equitable lien is extinguished.

In a dual-obligation case, the pharmacy lien payment goes directly from the attorney's trust account to the pharmacy. This is a traceable, identifiable disbursement to a specific creditor — not dissipation. But remaining funds disbursed to the client for general living expenses are non-traceable under Montanile.

The strategic implication: pay the pharmacy lien from the trust account, notify the ERISA plan of the impending disbursement of remaining funds to the client, and use the Montanile deadline pressure to force the plan to finalize its subrogation amount promptly.

[!TIP] Notify the ERISA plan in writing before disbursing remaining settlement funds to the client. Give the plan a reasonable deadline (14 to 21 days) to finalize the negotiated subrogation amount. This creates urgency without dissipating funds prematurely, preserving good faith while leveraging Montanile's framework.

The MERIT Report as Allocation Documentation

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. In cases involving ERISA subrogation, the MERIT report serves a dual purpose.

First, it documents the medications dispensed under the pharmacy lien with clinical detail sufficient to support the damages claim. Second, it provides a clear, pharmacist-verified record that these specific medications were dispensed outside the health plan system. When the TPA's subrogation demand arrives, the MERIT report is direct evidence that the plan did not pay for those medications and has no subrogation interest in them.

Related Resources

• ERISA Self-Funded Plans and Pharmacy Liens: What PI Attorneys Must Know
• Insured vs Self-Funded ERISA Plans: State Law Protection
• ERISA Preemption Case Study: Pharmacy Lien Survives Subrogation Claim